ArticleFrontiers in cellular and infection microbiology2018
Cas1 and Cas2 From the Type II-C CRISPR-Cas System of
Article in Frontiers in cellular and infection microbiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 24 citations in OpenAlex.
- DNA targeting by compact Cas9d and its resurrected ancestor.Nature communications · 2025Article
- Disparate mechanisms counteract extraneous CRISPR RNA production in type II-C CRISPR-Cas systems.microLife · 2025Article
- Adaptation by Type V-A and V-B CRISPR-Cas Systems Demonstrates Conserved Protospacer Selection Mechanisms Between Diverse CRISPR-Cas Types.The CRISPR journal · 2022Article
- Adaptation by Type III CRISPR-Cas Systems: Breakthrough Findings and Open Questions.Frontiers in microbiology · 2022Review
- The core Cas1 protein of CRISPR-Cas I-B inCurrent research in microbial sciences · 2021Article
- Article
- Cooperation between Different CRISPR-Cas Types Enables Adaptation in an RNA-Targeting System.mBio · 2021Article
- Comparative genomics and metabolomics analysis of Riemerella anatipestifer strain CH-1 and CH-2.Scientific reports · 2021Article
- Genome editing technologies: CRISPR, LEAPER, RESTORE, ARCUT, SATI, and RESCUE.EXCLI journal · 2021Review
- Campylobacter bacteriophage DA10: an excised temperate bacteriophage targeted by CRISPR-cas.BMC genomics · 2020Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated (Cas) proteins provide acquired genetic immunity against the entry of mobile genetic elements (MGEs). The immune defense provided by various subtypes of the CRISPR-Cas system has been confirmed and is closely associated with the formation of immunological memory in CRISPR arrays, called CRISPR adaptation or spacer acquisition. However, whether type II-C CRISPR-Cas systems are also involved in spacer acquisition remains largely unknown. This study explores and provides some definitive evidence regarding spacer acquisition of the type II-C CRISPR-Cas system from
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.